Search results
Results From The WOW.Com Content Network
Narrow-spectrum antibiotic allow to kill or inhibit only those bacteria species that are unwanted (i.e. causing disease). As such, it leaves most of the beneficial bacteria unaffected, hence minimizing the collateral damage on the microbiota. [2] [3] Low propensity for bacterial resistance development. [4]
The following is a list of antibiotics. ... May be more narrow-spectrum than vancomycin, resulting in less bowel microbiota alteration. [9] Nausea (11%), vomiting ...
Narrow-spectrum antibiotics have low propensity to induce bacterial resistance and are less likely to disrupt the microbiome (normal microflora). [3] On the other hand, indiscriminate use of broad-spectrum antibiotics may not only induce the development of bacterial resistance and promote the emergency of multidrug-resistant organisms, but also cause off-target effects due to dysbiosis.
Due to their narrow spectrum, monobactams can be used to treat infections by susceptible bacteria without disrupting the patient's microbiota. [2] Monobactams are nevertheless seldom used. [2] [6] Other monobactams include tigemonam, [7] nocardicin A, carumonam and tabtoxin.
This is a list of common β-lactam antibiotics—both administered drugs and those not in clinical use—organized by structural class. Antibiotics are listed alphabetically within their class or subclass by their nonproprietary name. If an antibiotic is a combination drug, both ingredients will be listed.
Sarecycline is a narrow-spectrum antibiotic. [56] [57] Omadacycline: 16+ hours (long) (formerly known as PTK-0796 [58]) received FDA approval on October 2, 2018, for treatment of community-acquired pneumonia [59] and acute skin and skin structure infections. [60]
Methicillin and other β-lactam antibiotics are structural analogs of D-alanyl-alanine, and the transpeptidase enzymes that bind to them are sometimes called penicillin-binding proteins (PBPs). [3] Methicillin is actually a penicillinase-resistant β-lactam antibiotic. Penicillinase is a bacterial enzyme produced by bacteria resistant to other ...
The first in a new class of narrow-spectrum macrocyclic antibiotics, fidaxomicin, has been approved for the treatment of C. difficile colitis. [162] New cephalosporin-lactamase inhibitor combinations also approved include ceftazidime-avibactam and ceftolozane-avibactam for complicated urinary tract infection and intra-abdominal infection.